Ide-cel Approved by FDA as Abecma in r/r MM After Four Lines of Previous Therapy

Late yesterday evening, BMS and bluebird bio announced US approval of ide-cel after completing at least 4 lines of prior therapy in r/r MM (BMS press release). The press release states that Abecma is a one-time infusion with a recommended dose range of 300 to 460 x 106 CAR-positive T cells. Of note, Abecma will be manufactured at BMS’s facility in Summit, New Jersey, with a median TAT of 33 days. The Celltelligence team will be conducting a full thoughts-on label review in the coming days (link to Abecma PI here).

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.